These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
435 related articles for article (PubMed ID: 26996405)
41. Liver injury associated with dimethyl fumarate in multiple sclerosis patients. Muñoz MA; Kulick CG; Kortepeter CM; Levin RL; Avigan MI Mult Scler; 2017 Dec; 23(14):1947-1949. PubMed ID: 28086032 [TBL] [Abstract][Full Text] [Related]
42. [In process]. Wagner B Med Monatsschr Pharm; 2016 Aug; 39(8):352-3. PubMed ID: 29984957 [No Abstract] [Full Text] [Related]
43. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT; N Engl J Med; 2012 Sep; 367(12):1098-107. PubMed ID: 22992073 [TBL] [Abstract][Full Text] [Related]
44. Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial. Højsgaard Chow H; Talbot J; Lundell H; Gøbel Madsen C; Marstrand L; Lange T; Mahler MR; Buhelt S; Holm Hansen R; Blinkenberg M; Romme Christensen J; Soelberg Sørensen P; Rode von Essen M; Siebner HR; Sellebjerg F Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34429340 [TBL] [Abstract][Full Text] [Related]
45. Diroximel fumarate to treat multiple sclerosis. Wang Y; Bhargava P Drugs Today (Barc); 2020 Jul; 56(7):431-437. PubMed ID: 32648853 [TBL] [Abstract][Full Text] [Related]
46. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150 [TBL] [Abstract][Full Text] [Related]
47. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective. Chevalier J; Chamoux C; Hammès F; Chicoye A PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055 [TBL] [Abstract][Full Text] [Related]
48. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
49. Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report. Patti F; Leone C; Zappia M BMC Neurol; 2015 Dec; 15():252. PubMed ID: 26643473 [TBL] [Abstract][Full Text] [Related]
50. [Oral disease-modifying agents in relapsing-remitting multiple sclerosis]. Iljicsov A; Pál Z; Simó M Neuropsychopharmacol Hung; 2015 Dec; 17(4):197-205. PubMed ID: 26727724 [TBL] [Abstract][Full Text] [Related]
51. Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate. Mayer L; Fink MK; Sammarco C; Laing L Drug Saf; 2018 Apr; 41(4):347-356. PubMed ID: 29218681 [TBL] [Abstract][Full Text] [Related]